Pneumococci Isolated From Children in Community-Based Practice Differ From Isolates Identified by Population- and Laboratory-Based Invasive Disease Surveillance

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Apr 9

PMID 38591247

Authors

Ravinder Kaur

Ryan Gierke

Lesley McGee

Eduardo Gonzalez

Miwako Kobayashi

Michael Pichichero

Affiliations

Soon will be listed here.

Abstract

Background: Characterizing strains causing noninvasive and invasive pneumococcal disease (IPD) may inform the impact of new pneumococcal conjugate vaccines (PCVs).

Methods: During 2011-2019, among children aged 6-36 months, pneumococcal serotype distribution and antibiotic nonsusceptibility of nasopharyngeal and middle ear fluid (MEF) isolates collected at onset of acute otitis media (AOM) in Rochester, New York, were compared with IPD isolates from the Active Bacterial Core surveillance (ABCs) system across 10 US sites.

Results: From Rochester, 400 (nasopharyngeal) and 156 (MEF) pneumococcal isolates were collected from 259 children. From ABCs, 907 sterile-site isolates were collected from 896 children. Non-PCV serotypes 35B and 21 were more frequent among the Rochester AOM cases, while serotypes 3, 19A, 22F, 33F, 10A, and 12F contained in PCVs were more frequent among ABCs IPD cases. The proportion of antibiotic-nonsusceptible pneumococcal isolates was generally more common among IPD cases. In 2015-2019, serotype 35B emerged as the most common serotype associated with multiclass antibiotic nonsusceptibility for both the Rochester AOM and ABCs IPD cases.

Conclusions: Pneumococcal isolates from children in Rochester with AOM differ in serotype distribution and antibiotic susceptibility compared to IPD cases identified through US surveillance. Non-PCV serotype 35B emerged as a common cause of AOM and IPD.

References

Ouldali N, Levy C, Varon E, Bonacorsi S, Bechet S, Cohen R . Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018; 18(9):983-991. DOI: 10.1016/S1473-3099(18)30349-9. View

Chichili G, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C . Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine. 2022; 40(31):4190-4198. DOI: 10.1016/j.vaccine.2022.05.079. View

Kaplan S, Barson W, Lin P, Romero J, Bradley J, Tan T . Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32(3):203-7. DOI: 10.1097/INF.0b013e318275614b. View

Moffitt K, Gierahn T, Lu Y, Gouveia P, Alderson M, Flechtner J . T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe. 2011; 9(2):158-65. PMC: 3061323. DOI: 10.1016/j.chom.2011.01.007. View

Chochua S, Metcalf B, Li Z, Walker H, Tran T, McGee L . Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015-2016. Emerg Infect Dis. 2017; 23(6):922-930. PMC: 5443455. DOI: 10.3201/eid2306.170071. View

Kaur R, Czup K, Casey J, E Pichichero M . Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014; 14:640. PMC: 4264249. DOI: 10.1186/s12879-014-0640-y. View

Heikkinen T, Chonmaitree T . Importance of respiratory viruses in acute otitis media. Clin Microbiol Rev. 2003; 16(2):230-41. PMC: 153141. DOI: 10.1128/CMR.16.2.230-241.2003. View

Kobayashi M, Farrar J, Gierke R, Britton A, Childs L, Leidner A . Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(4):109-117. PMC: 9351524. DOI: 10.15585/mmwr.mm7104a1. View

Kaur R, Morris M, E Pichichero M . Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era. Pediatrics. 2017; 140(3). PMC: 5574724. DOI: 10.1542/peds.2017-0181. View

10.

Yildirim I, Little B, Finkelstein J, Lee G, Hanage W, Shea K . Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness. Vaccine. 2017; 35(32):4002-4009. DOI: 10.1016/j.vaccine.2017.05.077. View

11.

Kaur R, Casey J, E Pichichero M . Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015. Pediatr Infect Dis J. 2016; 35(8):901-6. PMC: 4948952. DOI: 10.1097/INF.0000000000001206. View

12.

Huang S, Johnson K, Ray G, Wroe P, Lieu T, Moore M . Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011; 29(18):3398-412. DOI: 10.1016/j.vaccine.2011.02.088. View

13.

Kaur R, Fuji N, E Pichichero M . Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis. 2021; 41(1):37-44. DOI: 10.1007/s10096-021-04324-0. View

14.

Desai A, Sharma D, Crispell E, Baughman W, Thomas S, Tunali A . Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia. Pediatr Infect Dis J. 2015; 34(11):1168-74. DOI: 10.1097/INF.0000000000000849. View

15.

Voysey M, Fanshawe T, Kelly D, OBrien K, Kandasamy R, Shrestha S . Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. Clin Infect Dis. 2017; 66(6):913-920. DOI: 10.1093/cid/cix895. View

16.

Platt H, Omole T, Cardona J, Fraser N, Mularski R, Andrews C . Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2022; 23(2):233-246. DOI: 10.1016/S1473-3099(22)00526-6. View

17.

Kaur R, Pham M, Yu K, E Pichichero M . Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis. 2020; 72(5):797-805. PMC: 7935395. DOI: 10.1093/cid/ciaa157. View

18.

Friedel V, Zilora S, Bogaard D, Casey J, Pichichero M . Five-year prospective study of paediatric acute otitis media in Rochester, NY: modelling analysis of the risk of pneumococcal colonization in the nasopharynx and infection. Epidemiol Infect. 2014; 142(10):2186-94. PMC: 9151263. DOI: 10.1017/S0950268813003178. View

19.

Cohen J, Khandavilli S, Camberlein E, Hyams C, Baxendale H, Brown J . Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PLoS One. 2011; 6(10):e25558. PMC: 3189185. DOI: 10.1371/journal.pone.0025558. View

20.

Nuorti J, Whitney C . Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-11):1-18. View